NCT01045915终止1 期
Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 6
- 主要终点
- Determination of Dose Limiting Toxicity defined as any grade 4 clinical, biological or any life-threatening ECG event occurring during the 9 weeks following treatment
研究概览
简要总结
The objective of the present trial is to evaluate the local and general safety of the intratumoural electrotransfer of increasing doses of Plasmid AMEP in patients suffering from advanced or metastatic melanoma and to identify doses that could be effective on cutaneous lesions in man.
详细描述
In this open, multicentre, dose escalation study, successive cohorts of 3 patients suffering from advanced or metastatic melanoma will be electrotransferred increasing doses of Plasmid AMEP into cutaneous melanoma lesions in 2 divided doses at one week interval.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-breast feeding female;
- •Aged between 18 and 75 years;
- •Stage IIIB, stage IIIC or stage IV melanoma with:
- •At least 2 cutaneous or subcutaneous non necrotic accessible tumours;
- •Tumour size of 1 to 1.5 cm diameter;
- •No minimum distance between the 2 selected lesions;
- •Progressive melanoma not responding to previous treatments or patients refusing other therapies;
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
- •For women of child-bearing age: effective contraception method (oral contraception or intra-uterine device) used for more than 2 months before the 1st administration and to be maintained for 3 months after the last administration of Plasmid AMEP;
- •Having given a written informed consent.
排除标准
- •Patients who can benefit from other melanoma treatments including surgery;
- •Significant cardiac arrhythmias, electronic pacemakers, defibrillators, or any implanted electronic device;
- •Recent (less than 6 months) acute vascular diseases (stroke, MI...);
- •Advanced peripheral arterial diseases, venous ulcers, or scleroderma;
- •History or treatment of seizures within the last 5 years;
- •Clinically significant abnormality at pre-study full physical examination;
- •Any clinically significant ECG abnormalities;
- •Prior systemic therapy or any other antineoplastic treatments within the last 4 weeks, radiotherapy or surgery unrelated to the fields in question are allowed;
- •Abnormal renal function (creatinine plasma level > ULN);
- •Abnormal liver function tests (any of the following):
- •PT < 70%, ASAT, ALAT, alkaline phosphatases, GGT and/or total bilirubin > ULN in the absence of liver metastasis;
- •PT < 70%, ASAT, ALAT > 2 ULN, alkaline phosphatases > 1.5 ULN, GGT > 5 ULN and/or total bilirubin > 3 ULN in the case of liver metastases;
- •Abnormal bone marrow function: haemoglobin < 10g/dL, WBC < 3.109 /L and/or platelet count < 100.103 /L;
- •Clinically significant abnormality in pre-study laboratory tests;
- •Evidence of significant active infection (e.g., pneumonia, wound abscess, etc);
- •Intractable coagulopathy;
- •Any significant disease, including psychiatric and dermatology diseases that may affect the proper evaluation of efficacy or safety;
- •Patients who had participated in another clinical trial in the last 30 days prior to enrolment in the present clinical trial;
- •Patients unwilling or unable to comply with protocol requirements and scheduled visits.
- •Note: patients with brain metastases, or waiting for other therapies (i.e. isolated limb perfusion) may be included.
研究组 & 干预措施
Plasmid AMEP electrotransfer
Experimental
干预措施: naked DNA coding for protein AMEP (Biological)
结局指标
主要结局
Determination of Dose Limiting Toxicity defined as any grade 4 clinical, biological or any life-threatening ECG event occurring during the 9 weeks following treatment
时间窗: 9 weeks
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
招募中
不适用
The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid TumorsIntratumoral InjectionCancerNCT06430515Wuxi People's Hospital200
撤回
1 期
Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic MelanomaMelanomaNCT01764009Valerio Therapeutics
已完成
2 期
Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).Mild-to-moderate DepressionNCT03909217The University of Hong Kong470
已完成
不适用
Safety & Effectiveness of TENS Weight Management Compared to a ShamObesity, MildNCT05675384Elira, Inc.395
终止
不适用
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight LossOverweightObesityNCT03299881Elira Therapeutics, Inc.77